Search
Karyopharm Therapeutics Inc
KPTIAdd to Watchlist
1.610USD
-0.010-0.62%
Close 09-11 16:00（ET）
36.40MMarket Cap
LossP/E TTM
After-hours 17:18 (ET)1.620USD+0.020+1.25%
After-hours 17:18 (ET)TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-0.62%
5 Days
-10.06%
1 Month
-19.10%
6 Months
-79.49%
Year to Date
-78.13%
1 Year
-75.04%
Key Figures
1.500Open
1.610High
924.03KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
4.07%Turnover Ratio
1.620Prev. Close
1.240Low
1.35MTurnover
LossP/E Static
-0.11P/B
0.00%Div Yield TTM
-150.48%ROA
10.99052wk High
452.92Volume Ratio
-76.42MNet Profit
22.68MShares
-16.1748EPS TTM
0.83Beta
--ROE
1.24052wk Low
22.84%Amplitude
96.45%Gross Margin
36.40MMarket Cap
-12.16Reward/Risk
7.16%Risk Rate
Karyopharm Therapeutics Inc's Score
0.02vs previous score
Forecast8.67
Financial Health7.44
Technical5.77
Valuation Dimensions9.40
Institutional Confidence5.00
Risk Assessment2.04
Media Coverage
Coverage Level
Very Low
Very High
Neutral
Analyst Rating
Karyopharm Therapeutics Inc Technical Analysis
Technical Indicators
Sell
Summary
Sell
Moving Average
Strong sell
Karyopharm Therapeutics Inc Latest Earnings Call Transcripts
Karyopharm (KPTI) Q2 2026 Earnings Call: Selinexor sNDA and Liquidity Focus
Karyopharm’s Q2 2026 earnings call covered $33.4 million in revenue, an August selinexor sNDA target, reaffirmed guidance and near-term liquidity risk.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
-2.32/-1.28
Revenue / Forecast
33.43M/32.19M
Karyopharm Therapeutics Inc Profile
SectorPharmaceuticals
Ticker SymbolKPTI
Number of employees279
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Commodore Capital LP | 8.65% |
| RA Capital Management, LP | 8.51% |
| T. Rowe Price Investment Management, Inc. | 6.62% |
| J. Wood Capital Advisors LLC | 3.48% |
| Shareholder Types | Proportion |
|---|---|
| Hedge Fund | 30.88% |
| Investment Advisor | 14.61% |
| Venture Capital | 9.19% |
| Investment Advisor/Hedge Fund | 4.42% |
Related Instruments
-0.65%
-0.29%
+0.33%
+0.83%
-0.54%
-0.23%
-1.34%
-0.75%
+0.25%
-2.14%
+0.17%
-0.17%
+0.12%
+0.07%
+0.02%
-1.48%
+0.04%
+0.83%
+5.38%
-0.61%Popular Instruments
52501.000
-52.000 (-0.10%)
29012.400
-356.500 (-1.21%)
7619.800
-36.800 (-0.48%)
14436.000
-20.000 (-0.14%)
63053.000
-1626.000 (-2.51%)
6300.800
-19.000 (-0.30%)
100.863
+2.506 (+2.55%)
332.270
+5.700 (+1.75%)
218.290
-0.070 (-0.03%)
4341.030
-7.020 (-0.16%)
FAQs
What is the current price of Karyopharm Therapeutics Inc (KPTI)?
The current price of Karyopharm Therapeutics Inc (KPTI) is 1.61.
What is the symbol of Karyopharm Therapeutics Inc?
The ticker symbol of Karyopharm Therapeutics Inc is KPTI.
What is the 52-week high of Karyopharm Therapeutics Inc?
The 52-week high of Karyopharm Therapeutics Inc is 10.99.
What is the 52-week low of Karyopharm Therapeutics Inc?
The 52-week low of Karyopharm Therapeutics Inc is 1.24.
What is the market capitalization of Karyopharm Therapeutics Inc?
The market capitalization of Karyopharm Therapeutics Inc is 36.40M.
Is Karyopharm Therapeutics Inc (KPTI) currently rated as Buy, Hold, or Sell?
According to analysts, Karyopharm Therapeutics Inc (KPTI) has an overall rating of Buy, with a price target of 7.25.
What is the Earnings Per Share (EPS TTM) of Karyopharm Therapeutics Inc (KPTI)?
The Earnings Per Share (EPS TTM) of Karyopharm Therapeutics Inc (KPTI) is -16.17.